IL1B and depressive symptom measurement: The promise of using drugs against IL-1 and microglial activation to treat CNS diseases is attested by the current clinical trials that use IL-1ra to treat cerebral stroke (119–121), fatigue in Sojegren’s syndrome (122), and minocycline to treat cerebral stroke (123, 124), cerebral hemorrhage (125), Parkinson’s disease (126, 127), epilepsy (128), bipolar and treatment resistant depression (129, 130), and schizophrenia (131).